Exelixis, Inc. (EXEL) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
EXEL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
EXEL Revenue Analysis (2014–2025)
As of March 2, 2026, Exelixis, Inc. (EXEL) generated trailing twelve-month (TTM) revenue of $2.29 billion, reflecting strong growth of +10.8% year-over-year. The most recent quarter (Q3 2025) recorded $597.8 million in revenue, up 5.2% sequentially.
Looking at the longer-term picture, EXEL's 5-year compound annual growth rate (CAGR) stands at +18.6%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $2.32 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows EXEL's business is primarily driven by Product, Gross (65%), Product (46%), and License (5%). With over half of revenue concentrated in Product, Gross, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and IBRX (+1026.0% YoY), EXEL has underperformed the peer group in terms of revenue growth. Compare EXEL vs INCY →
Peer Comparison
Compare EXEL's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EXELCurrent | $2.3B | +10.8% | +18.6% | 37.6% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% | |
| CGON | $1M | +217.8% | - | -10067.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.32B | +7.0% | $0 | - | $872.2M | 37.6% |
| 2024 | $2.17B | +18.5% | $2.09B | 96.5% | $604.6M | 27.9% |
| 2023 | $1.83B | +13.6% | $1.76B | 96.0% | $170.9M | 9.3% |
| 2022 | $1.61B | +12.3% | $1.55B | 96.4% | $201.5M | 12.5% |
| 2021 | $1.43B | +45.3% | $1.38B | 96.3% | $286.7M | 20.0% |
| 2020 | $987.5M | +2.0% | $951.3M | 96.3% | $110.1M | 11.1% |
| 2019 | $967.8M | +13.3% | $934.7M | 96.6% | $369.5M | 38.2% |
| 2018 | $853.8M | +88.7% | $827.5M | 96.9% | $438.9M | 51.4% |
| 2017 | $452.5M | +136.3% | $437.4M | 96.7% | $165.9M | 36.7% |
| 2016 | $191.5M | +415.0% | $184.9M | 96.6% | $-28,124,000 | -14.7% |
See EXEL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EXEL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare EXEL vs AGIO
See how EXEL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is EXEL's revenue growth accelerating or slowing?
EXEL maintains +10.8% revenue growth, in line with its 5-year CAGR of +18.6%. TTM revenue stands at $2.3B. Growth rate remains consistent with historical average.
What is EXEL's long-term revenue growth rate?
Exelixis, Inc.'s 5-year revenue CAGR of +18.6% reflects the sustained expansion pattern. Current YoY growth of +10.8% is near this long-term average.
How is EXEL's revenue distributed by segment?
EXEL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.